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Abstract
Similarly to soft tissue tumours, the World Health Organisation (WHO) classification categorises bone tumours 
based on their similarity to normal adult tissue. The most recent WHO classification provides an updated classi-
fication scheme that integrates the biological behaviour of bone tumours, particularly cartilage-forming tumours, 
and tumours are now further subdivided as benign, intermediate (locally aggressive or rarely metastasising), and 
malignant. Radiologists play an important role in the detection and initial characterisation of bone tumours, with 
careful analysis of their matrix mineralisation, location, and overall anatomic extent including extra-compartmental 
extension and neurovascular invasion. Radiography remains central to the detection and characterisation of bone 
tumours; however, magnetic resonance imaging (MRI) is the ideal modality for local staging. This review will discuss 
the most recent updates to the WHO classification of bone tumours that are relevant to radiologists in routine clinical 
practice. The utility of advanced MRI sequences such as diffusion-weighted imaging, dynamic contrast enhanced 
sequences, and magnetic resonance spectroscopy that may provide insight into the biological behaviour of various 
bone tumours is highlighted. 
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Introduction
Primary skeletal tumours are exceedingly rare. The vast 
majority of clinically encountered bone tumours are 
benign with excellent prognosis with or without cura-
tive surgical excision. Similar to soft tissue tumours, the 
World Health Organisation (WHO) classification catego-
rises bone tumours based on their similarity to normal 
adult tissue [1]. Namely, each bone tumour is classified 
based on its similarity to normal adult tissue, as chondro-
genic tumours, osteogenic tumours, fibrogenic tumours, 
fibrohistiocytic tumours, ewing sarcoma, osteoclastic 
giant cell-rich tumours, notochordal tumours, vascular 
tumours, hematopoietic neoplasms and myogenic, lipo-
genic, and epithelial tumours, tumours of undefined neo-
plastic nature, and lastly undifferentiated high-grade pleo-
morphic sarcoma. The most recent WHO classification 
provides an updated classification scheme that integrates 
biological behaviour as a distinguishing feature in each 
subcategory; bone tumours, particularly cartilage forming 
tumours, are further subdivided as benign, intermediate 
(locally aggressive or rarely metastasising), and malignant 
tumours.
Only a small proportion of bone tumours are malig-
nant; however, their infrequent occurrence poses a man-
agement challenge to radiologists. For optimal results, 
bone tumours should be managed at an experienced 
tertiary referral centre with a multidisciplinary team 
consisting of a musculoskeletal radiologist, orthopaedic 
oncologist, and musculoskeletal pathologist. The radiolo-
gist must be familiar with the imaging appearance of bone 
tumours to initiate the referral to an orthopaedic oncolo-
gist in the appropriate clinical setting. Radiography plays 
an important role in the detection and characterisation 
of bone tumours; however, magnetic resonance imaging 
(MRI) is the optimal modality for assessment of the ana-
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tomic extent and locoregional staging. With the advent 
of advanced MRI sequences such as diffusion-weighted 
imaging (DWI), dynamic contrast enhanced sequences 
(DCE), and MR spectroscopy, MRI is gaining acceptance 
as a method of characterising the biological behaviour of 
a bone tumour. This review will discuss the most recent 
updates to the WHO classification of bone tumours that 
are relevant to radiologists in routine clinical practice and 
how these advanced MRI sequences can help solve chal-
lenging clinical dilemmas.
Chondrogenic tumours
Chondrogenic tumours of bone are now classified as 
benign, intermediate (locally aggressive), intermedi-
ate (rarely metastasising), and malignant grades. One 
of the major updates in this category includes the ad-
dition of osteochondromyxoma to the benign cat-
egory in addition to subungual exostosis, bizarre 
parosteal osteochondromatous proliferation, and sy-
novial chondromatosis. Osteochondromyxomas are 
extremely rare bone tumours observed in 1% of all 
patients with Carney complex, a cancer predisposi-
tion syndrome [2]. Chondromyxoid fibroma and atypi-
cal cartilaginous tumour/chondrosarcoma grade I 
are grouped together as intermediate (locally aggressive) 
tumours. Chondroblastoma (Figure 1) is classified as an 
intermediate (rarely metastasising) tumour. Malignant 
chondrogenic tumours (Figure 2) include grade II or III a, 
dedifferentiated, mesenchymal, and clear cell varieties 
of chondrosarcoma (CS). CS can be conceptualised as 
primary or secondary. Primary CS occurs de novo while 
secondary CS occurs in the setting of a pre-existing be-
nign chondrogenic skeletal lesion. Secondary CS can be 
central (arising in a pre-existing enchondroma) or periph-
eral (juxtaposed to the cartilaginous cap of an osteochon-
droma) type.
A major diagnostic dilemma for the radiologist in-
cludes the distinction between a large benign chondro-
genic lesion, such as an enchondroma, from a grade I CS 
or atypical cartilaginous tumour. (In general, enchondro-
ma is readily distinguished from grade II or III CS based 
on imaging.) Clinical and radiographic features useful 





Figure 1. 52-year-old woman with chondroblastoma, an intermediate (rarely metastasising) chondrogenic bone tumour. Anteroposterior radiograph of the 
left knee (A) shows a focal lytic skeletal lesion in the distal medial femoral condyle complicated with pathological fracture (arrow). On magnetic resonance 
imaging (MRI), there is a distal left femoral subarticular skeletal lesion (arrow) that is isointense to skeletal muscle on T1-weighted image (B), hyperintense 
to skeletal muscle on axial fat-suppressed (FS) T2-weighted image (C) with confluent internal enhancement on axial T1-weighted FS post-contrast image (D) 
and early arterial enhancement on dynamic contrast-enhanced-maximum intensity projection (E). Axial diffusion-weighted imaging (DWI) through the 
distal left femur using low b-value of 50 s/mm² (F), intermediate b-value of 400 s/mm² (G), high b-value of 800 s/mm² (H) and lastly the apparent diffusion 
coefficient (ADC) map (I) shows qualitative restricted diffusion with lack of signal loss on DWI progressively increasing b-values as well as low ADC values 
(≤ 1.0 × 10-3 mm2/s) ranging from 0.8 to 1.2. MRI is optimal for local staging and readily displays cortical breach on the coronal T1-weighted image (dotted 
arrow on image B). Advanced MRI features (early arterial enhancement on dynamic contrast enhanced and restricted diffusion on DWI/ADC mapping) point 
towards aggressive biology and hypercellularity
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pain attributable to the skeletal lesion of concern, lesion 
length, endosteal scalloping > 2/3, cortical destruction, 
bone expansion, and soft tissue extension [3]. Of these 
multi-parametric imaging features, endosteal scalloping 
greater than 2/3rd of the cortex has been shown to offer 
the highest sensitivity (71% CI: 42-92%), although corti-
cal destruction and the presence of soft tissue mass can 
provide perfect specificity of 100% [3]. DCE MRI has 
provided variable clinical experience for this purpose, 
with one investigation reporting limited utility [3] while 
another investigation [4] reporting 100% sensitivity and 
63.3% specificity and 93.4% overall accuracy for the dis-
tinction of enchondroma from grade I CS. DWI with ap-
parent diffusion coefficient (ADC) mapping is not a use-
ful imaging modality to distinguish a low-grade CS from 
enchondroma, probably due to the intrinsic T2 proper-
ties of chondroid lesions. According to one investigation, 
minimum ADC values (× 10-3 mm2/s) for enchondromas, 
low-grade (grade I) CS, high-grade (grade II and III) CS, 
and dedifferentiated CS were 1.82, 1.75 to 2.01, 1.83 to 
1.75, and 0.77, respectively, suggesting overlapping quan-
titative ADC values between all groups with the exception 
of dedifferentiated CS [5]. 
Therefore, challenging chondrogenic tumours require 
a multi-disciplinary approach and discussion between 
musculoskeletal radiologists, pathologists, and surgical 
oncologists to correlate clinical findings with radiologi-
cal findings, and the need for a biopsy as well as optimal 
biopsy track [6]. 
Osteogenic tumours
Osteogenic tumours can be benign (osteoma and osteoid 
osteoma), intermediate or locally aggressive (osteoblasto-
ma) (Figure 3), and malignant (osteosarcoma) (Figure 4). 
Other than the addition of osteoma to the benign os-
teogenic tumour category and distinguishing it from 
osteoid osteoma, the classification has not changed. Un-
like chondrogenic tumours, the distinction between be-
nign, intermediate, and malignant osteogenic tumours 
is less challenging. Recent advances include incorpora-
tion of baseline MRI using DWI-derived ADC values 
Figure 2. 25-year-old woman with grade 3 chondrosarcoma. Axial computed tomography (CT) image through the lower lumbar (A) spine shows an aggres-
sive, permeative skeletal lesion (arrow) within the vertebral body and posterior elements with a large soft tissue component arising from the left transverse 
process. Axial T1-weighted (B) and T2-weighted magnetic resonance (MR) images (C) through the lumbar spine are superior to CT in demonstrating the 
large associated soft tissue mass (arrows) and intraspinal extension of neoplasm. Coronal post-contrast T1-weighted fat-suppressed MR image through the 
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as a method of treatment response [7]. ADC values can 
provide information regarding the cellularity of a tumour 
of interest, with high ADC values typically present in 
hypocellular/necrotic or treatment-responsive tumours 
and low ADC values typically observed in hypercellular 
or treatment non-responsive tumours. Specifically for 
patients with osteosarcoma, post-treatment minimum 
ADC values (1.49 ± 0.38 × 10-3 mm2/s) tend to be higher 
than pre-treatment minimum ADC values (0.88 ± 0.16 
× 10-3 mm2/s) and different between patients with a good 
versus poor response to treatment (good response: 1.01 
± 0.22 × 10-3 mm2/s versus poor response: 0.55 ± 0.29 
× 10-3 mm2/s, p < 0.05) [8]. Interestingly, the underlying 
histologic subtype of osteosarcoma can have implications 
A B C
Figure 3. 14-year-old male with osteoblastoma and secondary aneurysmal bone cyst. Axial computed tomography image through the lower lumbar spine (A) 
shows an expansile, predominantly lucent, well-demarcated skeletal lesion (arrow) in the vertebral body extending posterior to involve the left pedicle 
and transverse process. Axial T1-weighted (B) and T2-weighted (C) magnetic resonance images through the skeletal lesion (arrow) show medial epidural 
extension of neoplasm (dotted arrow). Note the absence of septations and fluid-fluid levels indicative of a typical aneurysmal bone cyst (see Figure 11 for 
comparison)
Figure 4. 66-year-old man with osteosarcoma, osteoblastic type, grade 3 (of 3) in the setting of prior radiation therapy for prostate carcinoma several years 
ago. Coronal (A) and axial (B) computed tomography images through the pelvis reveal a large aggressive skeletal lesion (arrow) in the right pubic body 
extending towards the acetabulum with osteoid matrix mineralisation. Axial T1-weighted magnetic resonance image through the pelvis (C) shows the 
anatomical extent of the lesion to involve the anterior right acetabulum (arrow)
A B
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for diffusion properties and ultimately the ADC value. 
For example, DWI enables quantitative evaluation of 
treatment-related necrosis in patients with osteosarco-
ma, who have undergone neoadjuvant chemotherapy via 
ADC values, and shows differences between viable neo-
plasm and necrosis in fibroblastic and osteoblastic osteo-
sarcomas; however, viable chondroblastic osteosarcoma 
has intrinsically high ADC values due to its cartilaginous 
composition, and it cannot be distinguished reliably from 
necrosis [9].
Future directions for the advancement of imaging 
of osteogenic tumours include the incorporation of ra-
diomics signatures extracted from multi-parametric 
baseline MRI to predict outcomes in patients with osteo-
sarcoma [10,11]. Preliminary machine learning-based 
investigations on radiomic data offer high sensitivity of 
100% (95% CI [100-100%]) and specificity of 86% (95% CI 
[60-111]) [12]. Such non-invasive methods of predicting 
chemotherapy response may be a way of personalising the 
treatment paradigm of each patient in the future [12].
Fibrogenic tumours
Fibrogenic tumours of bone can be benign (desmoplastic 
fibroma) and malignant (fibrosarcoma). The major clari-
fication in the most recent WHO classification of tumours 
of bone and soft tissues is that fibrosarcoma is a diagno-
sis of exclusion and therefore requires a generous biopsy 
sample to make the correct diagnosis [1]. By definition, 
the diagnosis of fibrosarcoma requires absence of any 
recognisable line of differentiation and as such requires 
a thorough and representative histological sample when 
a biopsy is performed. On MRI, fibrosarcomas (Figure 5) 
tend to have similar imaging features as other sarcomas; 
namely, fibrosarcomas are hypointense relative to skeletal 
muscle on T1-weighted imaging, heterogeneous with low 
and high signal intensity on T2-weighted images with 
variable enhancement, perilesional oedema, and internal 
septae [13]. No unique advanced MRI features of fibro-
sarcoma have been described, but they probably overlap 
with other malignant tumours. Fibrosarcoma of bone and 
Figure 5. 44-year-woman with fibrosarcoma of bone. Anteroposterior radiograph of the left humerus (A) shows a lytic lesion (arrow) in the proximal humeral 
diaphysis complicated with a pathological fracture. Magnetic resonance imaging (MRI) shows intramedullary marrow replacement, cortical break, as well 
as perilesional oedema/periosteal reaction on axial T2-weighted fat-suppressed (B) and T1-weighted images (C) through the left humerus (arrows). There 
are no determinate features on radiographs or MRI. By definition, the diagnosis of fibrosarcoma requires absence of any recognisable line of differentiation 
and as such requires a thorough and representative histological sample when a biopsy is performed
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undifferentiated high-grade pleomorphic sarcomas are 
treated in a similar manner as osteosarcoma.
Ewing sarcoma
An additional major update in the most recent WHO 
classification of tumours of bone and soft tissues is the 
removal of the term “PNET” as a synonym for Ewing sar-
coma. Although the diagnosis of Ewing sarcoma is made 
on radiography and histology, MRI plays an important 
role for locoregional staging (Figure 6). Similar to osteo-
sarcoma, there is increasing interest in the utility of ad-
vanced MRI sequences for the initial assessment of Ewing 
sarcoma [14]. Because DWI investigates intratumoural 
cellularity with a small perfusion-related contribution, 
it can provide important insight into tumour aggressiv-
ity; information that can be used to predict treatment 
response. Investigations of Ewing sarcoma focusing on 
conventional non-contrast and contrast-enhanced MRI 
sequences in addition to DWI have shown agreement 
for tumour size, with significant associations for necrosis 
(p = 0.02), neurovascular invasion (p < 0.001), and en-
larged lymph nodes (p = 0.005), with overall high diag-
nostic accuracy [14]. Interestingly, the combination of 
conventional MRI and DWI had comparable diagnostic 
accuracy to conventional and contrast-enhanced MRI, 
but it had superior diagnostic performance to conven-
tional sequences alone. However, there was no correlation 
(p > 0.05) between minimum ADC values and relative 
enhancement, suggesting that the two techniques may be 
independent and provide separate information regard-
ing tumour biology [14]. In addition to baseline MRI, 
the added value of advanced MRI sequences has been 
explored for the assessment of treatment response. As ex-
pected, and similarly to treatment response in osteosar-
coma, treated Ewing sarcomas (1.03 ± 0.31 × 10-3 mm2/s) 
tend to demonstrate higher ADC values on DWI when 
compared with untreated Ewing sarcomas (0.48 ± 0.16 × 
10-3 mm2/s) [15]. 
Osteoclastic giant cell-rich tumours 
Osteoclastic giant cell-rich tumours (Figure 7) can be be-
nign giant cell lesions of the small bones, intermediate 
locally aggressive or rarely metastasizing giant cell tumour 
of bone (GCTB) and lastly, malignant GCT of bone. The 
biological behavior of GCTB can be variable with locally 
aggressive forms and rarely metastasizing forms [16]. 
Although complete removal or enbloc resection is the 
optimal treatment of choice, it can be challenging when 
GCTB occurs in the sacrum or is in a subarticular loca-
tion [17]. As such, intralesional curettage with adjuvant 
treatment is an attractive alternative for improved func-
tional outcome; however, it has a higher recurrence rate. 
Interestingly, the recurrence tends to be located in the pe-
riphery [18]. Therefore, MRI can play an important role in 
Figure 6. 11-year-old female with Ewing sarcoma. Oblique radiograph of the left ankle (A) shows an aggressive lytic lesion (arrow) in the distal tibia involv-
ing the diametaphysis with cortical destruction and associated extra-osseous extension. Magnetic resonance imaging shows large skeletal lesion (arrow) 
measuring 3.5 × 2.6 × 6.2 cm with demonstration of its intramedullary extent as well as large associated soft tissue mass on coronal T1-weighted (B), axial 
T2-weighted fat-suppressed (FS) and (C) axial T1-weighted FS post-contrast images (D) through the left distal tibia (arrows)
A B C
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locoregional staging and selection of intralesional margins 
to strike a balance between optimal oncologic and func-
tional outcome. On MRI, GCTB margins can be classified 
as clear, relatively clear, or blurred, which correlate with 
local tumour cell infiltration on histology [19]. The “paint-
brush border” signs as detectable by MRI on T1-weighted 
images, has been correlated with local tumour cell infiltra-
tion on histology [20].
Fibrohistiocytic tumours
Fibrohistiocytic tumours of bone include benign lesions 
such as benign fibrous histiocytoma or non-ossifying fi-
broma. Similar to the edition in soft tissue tumour, the 
term “malignant fibrous histiocytoma” has been removed 
and renamed undifferentiated high-grade pleomorphic 
sarcoma of bone (UHGPS).
Notochordal tumours 
Notochordal tumours of bone can be categorized as be-
nign notochordal tumour (BNT) or malignant (chordo-
ma). The addition of BNT to the benign category in this 
group is a new addition to the most recent WHO clas-
sification of tumours of bone. BNT can usually be distin-
guished from chordoma based on its imaging appearance. 
BNT tend to occur in the vertebra without expansion, cor-
tical destruction or associated soft tissue mass. On MRI, 
BNT has elevated T2 signal and low T1 signal relative to 
skeletal muscle with minimal associated sclerosis on com-
puted tomography (CT) [21]. Chordomas (Figure 8), on 
the other hand, tend to be expansile, lytic skeletal lesions 
with a soft tissue mass [21]. 
Although the immunohistochemical profile of chor-
doma (expression of brachyury) is different than CS 
(IDH1 and IDH2 mutations), the two entities can have 
an overlapping imaging appearance, particularly on fluid-
sensitive sequences. Both lesions tend to be T1 hypoin-
tense and T2 hyperintense with little to no enhancement 
associated with chordomas and variable enhancement of 
CS [21]. Small single-centre investigations have reported 
on the utility of quantitative DWI and ADC mapping 
as a useful tool to distinguish these two entities [22,23]. 
The solid component of CS tends to have overall higher 
minimum, mean, and maximum ADC values compared 
with chordomas, with the mean ADC cut-off point of 
1.6 × 10-3 mm2/s offering a sensitivity and specificity of 
94.3% and 98.6%, respectively [22]. DWI can distinguish 
CS from both classic and poorly differentiated chordo-
ma [23]. There is emerging interest in radiomics [24] as 
Figure 7. 18-year-old male with giant cell tumour of bone. Anteroposterior radiograph of the left knee (A) shows a focal, subarticular lytic lesion in the 
proximal tibia involving the tibial spine (arrow). Magnetic resonance imaging (MRI) shows a focal skeletal lesion (arrow) on coronal T1-weighted (B), coronal 
T2-weighted fat-suppressed (FS), and (C) coronal T1-wighted FS post-contrast images (D) through the left proximal tibia with marked perilesional bone 
marrow and soft tissue oedema and enhancement. MRI can play an important role in locoregional staging of giant cell tumour of bone and selection of 
intralesional margins to strike a balance between optimal oncological and functional outcome. On MRI, giant cell tumour of bone margins can be classified 
as clear (as seen here), relatively clear, or blurred, which correlate with local tumour cell infiltration on histology
A B C D
Figure 8. 56-year-old male with C3 chordoma. Axial T2-weighted (A), T1-weighted (B), and GRE-based (C) magnetic resonance images through C3 vertebra 
show an expansile, T2 hyperintense, marrow replacing lesion (arrow) involving the right C3 vertebral body with a ventral soft tissue component. There is no 
intra-lesional mineralised matrix on the coronal computed tomography image (D) or GRE
A B C D
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a non-invasive multi-parametric tool to distinguish chor-
doma from chondrosarcoma with high diagnostic accu-
racy (92% [95% CI: 89-95%] in the primary cohort and 
89% [95% CI: 86-931%]) in the validation cohort, and the 
specificity was 92% (95% CI: 90-94%) and 67% (95% CI: 
63-70%) in the primary and validation cohorts, respec-
tively [24]. In addition, there has been limited work us-
ing advanced MRI techniques and multi-parametric CT 
and MRI data to distinguish sacral GCTB and chordoma. 
Although both lesions occur in the sacrum, they tend to 
manifest distinct T2 signatures with GCTB tending to 
be relative hypointense and chordoma tending to be hy-
perintense. As such, a radiomics model based on DWI 
(exploiting the T2 properties of a tissue of interest) tends 
to have a higher area under the curve (AUC) of 0.89 for 
individual scans when compared with CT enhancement, 
T1-weighted, T2-weighted, and contrast-enhanced T1-
weighted features for distinguishing GCTB from chor-
doma [25]. When clinical data including age, sex, and tu-
mour location are incorporated into a clinical-radiomics 
nomogram, the AUC can be as high as 0.95 [25] for dis-
tinguishing GCTB and chordoma.
Myogenic, lipogenic, and epithelial tumours
Tumours in this category include lipoma, adamantinoma, 
leiomyosarcoma, and lastly liposarcoma. Of these four en-
tities, adamantinoma can be challenging to diagnose cor-
rectly on imaging as well as histology, even though there 
are important treatment implications to this diagnosis. 
Osteofibrous dysplasia (OFD), osteofibrous dysplasia-like 
adamantinoma (OFD/LA), and adamantinoma are rare 
bone tumours that preferentially affect the tibial diaphysis. 
Of these, adamantinoma, a rare malignant tumour, can 
be challenging to definitively diagnose on percutaneous 
biopsy, and as such, radiologists play an important part in 
Figure 9. 16-year-old female with polyostotic epithelioid haemangioendothelioma (EHE) in the right lower extremity. Lateral radiograph of the right ankle (A) 
shows multifocal mixed lytic and sclerotic skeletal lesions in the distal tibia (long arrow), posterior calcaneus (dotted arrow, complicated with pathological 
fracture), and talus (short arrow). On magnetic resonance imaging (MRI), there are multifocal skeletal lesions in the distal tibia (long arrow), posterior calca-
neus (dotted arrow, complicated with pathological fracture), and talus (short arrow). These lesions are isointense to skeletal muscle on sagittal T1-weighted 
image (B) and hyperintense to skeletal muscle on axial T2-weighted fat-suppressed image (C). Axial diffusion-weighted imaging (DWI) through the distal 
left tibia (arrow) using low b-value of 50 s/mm² (D), intermediate b-value of 400 s/mm² (E), high b-value of 800 s/mm² (F), and the apparent diffusion 
coefficient (ADC) map (G) show qualitative free diffusion with progressive signal loss on DWI with progressively increasing b-values as well as high ADC values 
(≤ 1.0 × 10-3 mm2/s) ranging from 1.5 to 2.2. Coronal dynamic contrast enhanced maximum intensity projection (H) shows multifocal sites of early arterial 
enhancement in the distal tibia (arrow), fibula, calcaneus, and talus, a distinguishing MRI feature of EHE when compared with epithelioid haemangioma
A
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radiology-pathology concordance or in suggesting repeat 
biopsy in the setting of discordance [26]. Unlike OFD and 
OFD/LA, adamantinoma tends to have permeative moth-
eaten margins and complete marrow replacement in the 
medullary cavity [26]. At this time, there are no investi-
gations regarding the utility of advanced MRI sequences 
such as DWI and DCE for the distinction of adamanti-
noma from OFD and OFD/LA.
Vascular tumours
Vascular tumours of bone can be benign (haemangioma), 
intermediate, or locally aggressive/rarely metastasising 
such as epithelioid haemangioma (EH), a new addition 
to this group, or malignant (angiosarcoma and now epi-
thelioid haemangioendothelioma [EHE]). The new clas-
sification now recognises EH as a separate entity that can 
be polyostotic. EH can be locally aggressive and can rarely 
present with lymphatic metastasis [27]. As opposed to EH, 
EHE (Figure 9) tends to have prominent flow voids and 
early arterial enhancement [28]. Again, there are no data 
regarding the advanced MRI features of EH or EHE, but 
DCE MRI may play an important role in distinguishing 
these two entities. 
Tumours of undefined neoplastic nature
Tumours of undefined neoplastic nature include aneu-
rysmal bone cyst (Figure 10), simple bone cyst, fibrous 
dysplasia, OFD, Langerhans cell histiocytosis (LCH), Erd-
heim-Chester disease, chondromesenchymal hamartoma, 
and Rosai-Dorfman disease. A combination of radio-
graphs and routine MRI sequences can readily diagnose 
aneurysmal bone cyst, unicameral bone cyst, and fibrous 
dysplasia. However, of these entities, LCH can have the 
most confounding appearance. Notably, LCH (Figure 11) 
can overlap with infection as well as malignancy because 
it demonstrates aggressive MRI features including per-
ilesional oedema, perilesional enhancement, periostitis, 
endosteal scalloping, and a soft tissue mass [29]. There are 
no data regarding the utility of advanced MRI sequences 
for the accurate distinction of LCH from other aggressive 
bone tumours, and frequently a biopsy is required.
Undifferentiated high-grade pleomorphic 
sarcoma
An additional major update in the most recent WHO 
classification of tumours of bone and soft tissues is the 
replacement of the term “malignant fibrous histiocytoma” 
with undifferentiated high-grade pleomorphic sarcoma of 
bone (UHGPS). Radiologic features of UHGPS include an 
aggressive, permeative lytic skeletal lesion with wide zone 
of transition that is T1-iso- to minimally hyperintense 
relative to skeletal muscle and minimally T2-hyperintense 
[30]. These tumours are treated similar to osteosarcomas. 
They can arise secondarily in pre-existing skeletal lesions 
or primary/de novo and are associated with a poor prog-
nosis (~ 53% five-year survival rate) [30].
Haematopoietic tumours and tumour syndromes
Haematopoietic tumours (plasma cell myeloma, solitary 
plasmacytoma, and primary non-Hodgkin lymphoma of 
Figure 10. 15-year-old male with right second rib aneurysmal bone cyst. Anteroposterior chest radiograph (A) shows an expansile lytic skeletal lesion 
involving the right second lateral rib (arrow) with a large intrathoracic subpleural component. On axial computed tomography image (B) there is no internal 
mineralised matrix (arrow). On magnetic resonance imaging, there are several fluid-fluid levels on axial T2-weighted fat-suppressed (FS) image (C), presence 
of T1 hyperintensity medially – probably representing haemorrhagic products on axial T1-weighted FS pre-contrast image (D) with thin septal enhancement 
on axial T1-weighted FS post-contrast imaging (E) compatible with primary aneurysmal bone cyst (arrows)
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bone) and tumour syndromes (Li Fraumeni syndrome, 
enchondromatosis, multiple hereditary exostosis, neuro-
fibromatosis, etc.) are not discussed because a thorough 
discussion is beyond the scope of this review.
Conclusions
The updated WHO classification of tumours of bone high-
lights new clinicopathological and genetic features to en-
able reliable and reproducible methods of diagnosis and 
lesion characterisation, which can then inform effective 
treatment selection. Radiography remains central to the 
detection and characterisation of bone tumours; however, 
MRI is not only optimal for locoregional staging but also 
for gaining wider acceptability for the characterisation of 
bone tumours. Although advanced MRI sequences such 
as DWI and DCE may provide insight into tumour biol-
ogy, clinical management of bone tumours ultimately re-
quires a multi-disciplinary approach with the radiologists 
playing an important role in this team.
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